Biothera
develops cancer immunotherapy to recognize and kill anti-body tumor cells... Read moreBiothera
develops cancer immunotherapy to recognize and kill anti-body tumor cells... Read more
News
Sep 09, 2020
The Center for Biosimilar
Biothera: Bio-Thera Begins Phase 1 Trial for Ustekinumab BiosimilarSeptember 3, 2020Skylar JeremiasArticleBio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.
Sep 03, 2020
Business Wire
Press Release: Biothera : Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara (Ustekinumab)
Aug 25, 2020
The Pharma Letter
Biothera: Bio-Thera Solutions sells China Avastin biosimilar rights for up to $165M
Jul 07, 2020
Newyork Citybizlist
Biothera: HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
Jun 22, 2020
The Center for Biosimilar
Biothera: Bio-Thera's Avastin Biosimilar Application Accepted by NMPA
Dec 12, 2019
centralcharts
Press Release: Biothera : Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium
Dec 04, 2019
Benzinga
Biothera: Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium
Nov 08, 2019
Benzinga
Biothera: Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study
Nov 05, 2019
Benzinga
Biothera: Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study
Sep 06, 2019
BioPortfolio
Biothera: Positive results for BioTheras arthritis copy biologicals
Biothera Competitors
1
2
3
4
5
6
7
8